AbbVie heads to the ITC in dramatic final battle over Humira biosimilars
Chicago-based company seeking to exclude Alvotech’s adalimumab product from the US market for alleged trade secret misappropriation
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.